Complement Activation in Progression of Chronic Kidney Disease

Area of Science:

• Nephrology
• Immunology
• Complement System Biology

Background:

• Chronic kidney disease (CKD) is a global health issue with rising prevalence.
• The exact mechanisms driving progression to end-stage renal disease (ESRD) remain unclear.
• The complement system, crucial for immunity, is increasingly implicated in renal disease pathogenesis.

Purpose of the Study:

• To elucidate the role of complement activation in chronic kidney disease progression.
• To explore the therapeutic potential of targeting the complement system in renal diseases.

Main Methods:

• Review of clinical and experimental studies on complement activation in kidney disease.
• Analysis of the mechanisms by which complement components (C3a, C5a, MAC) mediate renal damage.
• Evaluation of complement-targeting therapeutics in preclinical models and clinical trials.

Main Results:

• Complement activation is a key factor in multiple renal diseases and fibrosis.
• Anaphylatoxins (C3a, C5a) and MAC contribute to renal injury via inflammation, chemotaxis, and renin-angiotensin system activation.
• Complement inhibitors have shown efficacy in animal models and in treating atypical hemolytic uremic syndrome (aHUS).

Conclusions:

• Complement activation is a significant driver of chronic kidney disease progression.
• Targeting the complement system represents a promising therapeutic strategy for renal diseases.
• Further development is needed to optimize complement inhibitors for widespread clinical use.